A prospect on the use of antiviral drugs to control local outbreaks of COVID-19

被引：0
|
作者：
Andrea Torneri
Pieter Libin
Joris Vanderlocht
Anne-Mieke Vandamme
Johan Neyts
Niel Hens
机构：
[1] University of Antwerp,Centre for Health Economic Research and Modelling Infectious Diseases
[2] Hasselt University,Interuniversity Institute of Biostatistics and Statistical Bioinformatics, Data Science Institute
[3] Vrije Universiteit Brussel,Artificial Intelligence Lab, Department of Computer Science
[4] KU Leuven - University of Leuven,Department of Microbiology and Immunology, Rega Institute for Medical Research, Clinical and Epidemiological Virology
[5] Universidade Nova de Lisboa,Center for Global Health and Tropical Medicine, Unidade de Microbiologia, Instituto de Higiene e Medicina Tropical
来源：
BMC Medicine | / 18卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Antiviral drugs prioritization for COVID-19 management based on rational selection
    Joshi, Rakesh S.
    Giri, Ashok P.
    Kulkarni, Mahesh J.
    Gupta, Mahesh
    Verma, Savita
    Chaudhry, Dhruva
    Deshmukh, Narendra
    Chugh, Anita
    CURRENT SCIENCE, 2021, 120 (09): : 1464 - 1470
  • [32] Antiviral drugs proposed for COVID-19: action mechanism and pharmacological data
    Rommasi, F.
    Nasiri, M. J.
    Mirsaiedi, M.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (11) : 4163 - 4173
  • [33] A tale of two antiviral targets - and the COVID-19 drugs that bind them
    Cully, Megan
    NATURE REVIEWS DRUG DISCOVERY, 2022, 21 (01) : 3 - 5
  • [34] Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant
    Takashita, Emi
    Kinoshita, Noriko
    Yamayoshi, Seiya
    Sakai-Tagawa, Yuko
    Fujisaki, Seiichiro
    Ito, Mutsumi
    Iwatsuki-Horimoto, Kiyoko
    Chiba, Shiho
    Halfmann, Peter
    Nagai, Hiroyuki
    Saito, Makoto
    Adachi, Eisuke
    Sullivan, David
    Pekosz, Andrew
    Watanabe, Shinji
    Maeda, Kenji
    Imai, Masaki
    Yotsuyanagi, Hiroshi
    Mitsuya, Hiroaki
    Ohmagari, Norio
    Takeda, Makoto
    Hasegawa, Hideki
    Kawaoka, Yoshihiro
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (10): : 995 - 998
  • [35] The in vitro Evaluation of the Activity of COVID-19 Antiviral Drugs Against Adenovirus
    Romanowski, Eric G.
    Yates, Kathleen A.
    Romanowski, John E.
    Shanks, Robert M. Q.
    Kowalski, Regis P.
    CLINICAL OPHTHALMOLOGY, 2021, 15 : 4787 - 4793
  • [36] Antimalarial and Antiviral Drugs: A Review of Trials and Effectiveness in Treating COVID-19
    Adwani, Chandra
    BIOSCIENCE BIOTECHNOLOGY RESEARCH COMMUNICATIONS, 2021, 14 (06): : 231 - 236
  • [37] Safety and Efficacy of Antiviral Drugs for the Treatment of COVID-19: A Systematic Review
    Nie, Zhenwang
    Sun, Tao
    Zhao, Fangcheng
    INFECTION AND DRUG RESISTANCE, 2022, 15 : 4457 - 4466
  • [38] Association of Antiviral Drugs for the Treatment of COVID-19 With Acute Renal Failure
    Kamo, Masahiro
    Sogawa, Rintaro
    Shimanoe, Chisato
    IN VIVO, 2024, 38 (04): : 1841 - 1846
  • [39] Virtual and In Vitro Antiviral Screening Revive Therapeutic Drugs for COVID-19
    Bocci, Giovanni
    Bradfute, Steven B.
    Ye, Chunyan
    Garcia, Matthew J.
    Parvathareddy, Jyothi
    Reichard, Walter
    Surendranathan, Surekha
    Bansal, Shruti
    Bologa, Cristian G.
    Perkins, Douglas J.
    Jonsson, Colleen B.
    Sklar, Larry A.
    Oprea, Tudor, I
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2020, 3 (06) : 1278 - 1292
  • [40] A tale of two antiviral targets — and the COVID-19 drugs that bind them
    Megan Cully
    Nature Reviews Drug Discovery, 2022, 21 : 3 - 5
12345